Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6961922 | 0.99 | HTR2C (0.61) | HTR2CHTR2AHTR2BHTR1AAKT1 | |
| Bicarbonate SCHEMBL7446322 | 0.95 | HTR2C (0.55) | HTR2CHTR2AHTR2BHTR1AAKT1 | |
| SCHEMBL26515976 | 0.83 | HTR2C (0.60) | HTR2CHTR2AHTR2BHTR1AAKT1 | |
| SCHEMBL23873173 | 0.83 | HTR2C (0.60) | HTR2CHTR2AHTR2BHTR1AAKT1 | |
| SCHEMBL26115367 | 0.83 | HTR2C (0.60) | HTR2CHTR2AHTR2BHTR1AAKT1 | |
| SCHEMBL6827407 | 0.82 | HTR2C (0.56) | HTR2CAKT1KCNH2 | |
| Hydrochloric Acid SCHEMBL6439125 | 0.82 | HTR2C (0.61) | HTR2CHTR2AHTR2BHTR1AAKT1 | |
| Hydrochloric Acid SCHEMBL6439127 | 0.82 | HTR2C (0.61) | HTR2CHTR2AHTR2BHTR1AAKT1 | |
| SCHEMBL17474595 | 0.81 | HTR2C (0.55) | HTR2CHTR2AHTR2BHTR1AAKT1 | |
| Hydrochloric Acid SCHEMBL4727677 | 0.81 | HTR2C (0.57) | HTR2CAKT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620102-B1 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| CN-1812790-A | 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor | WYETH CORP (US) | 2006-08-02 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6124323-A | ACTIVE DRUG TREATING STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMIOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE HEADACHES, CHRONIC PAIN, GLAUCOMA, CMV RETINITIS, PSYCHOSIS | WARNER-LAMBERT COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| WO-1996002250-A1 | HALOPERIDOL ANALOGS AND THE USE THEREOF | ACEA PHARMACEUTICALS INC. (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | HTR2C 4362/4885HTR2A 4207/4885HTR2B 3054/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | HTR2C 4439/4885HTR2A 3829/4885HTR2B 3752/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | HTR2C 2451/4885HTR2A 1428/4885HTR2B 1359/4885 |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | HCAR2, PCCA, MCCC2 | HTR2C 4322/4885HTR2A 3805/4885HTR2B 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.